Literature DB >> 19942260

Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis.

Limei Yang1, Weihong Ge, Feng Yu, Huaijun Zhu.   

Abstract

INTRODUCTION: Warfarin is the most widely used oral anticoagulant. It has been suggested that anticoagulation effect of warfarin is significantly associated with the polymorphism of certain genes, including Cytochrome P450 complex subunit 2C9 (CYP2C9), Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1), Gamma-Glutamyl Carboxylase (GGCX) and Apolipoprotein E (APOE) etc. The purpose of the present study was to conduct a systemic review and meta-analysis to investigate the relationship between mean daily warfarin dose (MDWD) and VKORC1 single nucleotide polymorphisms (SNPs).
MATERIALS AND METHODS: Inclusion and exclusion criteria were made, and the studies between 2004 and present were searched. References were examined, and experts were consulted for additional information. Data were extracted. Revman 4.2.10 software was applied to analyze the relationship between MDWD and VKORC1 SNPs.
RESULTS: Total 19 studies were included in the meta-analysis. The frequencies of 1173TT and -1639 AA in Asian patients were higher than those in Caucasian and African populations. Patients with VKORC1 1173 CT and 1173 CC required 44% [95% Confidence Interval (CI); 32%, 56%] and 97% [73%, 122%] higher MDWD than 1173 TT carriers, -1639GA and -1639GG carriers required 52% [41%, 64%] and 102% [85%, 118%] higher MDWD than -1639AA carriers, 3730GA and 3730AA carriers required 27% [3%, 58%] and 52% [3%, 109%] higher MDWD than 3730GG carriers. In addition, 1173C, -1639 G and 3730 A carriers required 63% [44%, 82%], 61% [49%, 73%] and 32% [4%, 59%] higher MDWD than 1173TT, -1639 AA and 3730GG, respectively. Sensitive analyses demonstrated that the impacts of gene polymorphism on warfarin dosage requirement were significantly different between Caucasian and Asian population, and the results of meta-analyses were stable and reliable.
CONCLUSION: This is the first meta-analysis about the impact of VKORC1 gene polymorphism on warfarin dose requirement. Our studies showed that gene polymorphisms of VKORC1 significantly associated with the variation of interindividual warfarin dose requirement variation, and the effects are different in ethnicities. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19942260     DOI: 10.1016/j.thromres.2009.10.017

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  34 in total

Review 1.  Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.

Authors:  Megan M Donohue; David L Tirschwell
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 2.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

3.  A population-based assessment of the drug interaction between levothyroxine and warfarin.

Authors:  D Pincus; T Gomes; C Hellings; H Zheng; J M Paterson; M M Mamdani; D N Juurlink
Journal:  Clin Pharmacol Ther       Date:  2012-10-24       Impact factor: 6.875

4.  Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.

Authors:  N S Bazan; N A Sabry; A Rizk; S Mokhtar; O A Badary
Journal:  Ir J Med Sci       Date:  2013-06-27       Impact factor: 1.568

5.  Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.

Authors:  Ahmet Kocael; Allison Pınar Eronat; Mete Bora Tüzüner; Ahmet Ekmekçi; Ahmet Lütfullah Orhan; İbrahim İkizceli; Hülya Yılmaz-Aydoğan; Oğuz Öztürk
Journal:  Mol Biol Rep       Date:  2019-02-02       Impact factor: 2.316

6.  The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.

Authors:  Susan I Vear; Gregory D Ayers; Sara L Van Driest; Robert F Sidonio; Charles Michael Stein; Richard H Ho
Journal:  Br J Haematol       Date:  2014-03-06       Impact factor: 6.998

7.  Pharmacogenetics of anticoagulants.

Authors:  Anders Rane; Jonatan D Lindh
Journal:  Hum Genomics Proteomics       Date:  2010-09-13

Review 8.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

9.  Warfarin pharmacogenomics in children.

Authors:  Susan I Vear; C Michael Stein; Richard H Ho
Journal:  Pediatr Blood Cancer       Date:  2013-05-16       Impact factor: 3.167

Review 10.  Pharmacogenomics and cardiovascular disease.

Authors:  Peter Weeke; Dan M Roden
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.